ES2894335T5 - Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune - Google Patents

Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune

Info

Publication number
ES2894335T5
ES2894335T5 ES16840215T ES16840215T ES2894335T5 ES 2894335 T5 ES2894335 T5 ES 2894335T5 ES 16840215 T ES16840215 T ES 16840215T ES 16840215 T ES16840215 T ES 16840215T ES 2894335 T5 ES2894335 T5 ES 2894335T5
Authority
ES
Spain
Prior art keywords
blockade
target cell
cell depletion
enhanced target
immune costimulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16840215T
Other languages
English (en)
Other versions
ES2894335T3 (es
Inventor
Peter Schnorr
Akanksha Chhabra
Judith A Shizuru
Irving L Weissman
Kipp Andrew Weiskopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58100930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2894335(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of ES2894335T3 publication Critical patent/ES2894335T3/es
Application granted granted Critical
Publication of ES2894335T5 publication Critical patent/ES2894335T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES16840215T 2015-08-26 2016-08-26 Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune Active ES2894335T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210279P 2015-08-26 2015-08-26
PCT/US2016/049016 WO2017035480A1 (en) 2015-08-26 2016-08-26 Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist

Publications (2)

Publication Number Publication Date
ES2894335T3 ES2894335T3 (es) 2022-02-14
ES2894335T5 true ES2894335T5 (es) 2024-06-27

Family

ID=58100930

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16840215T Active ES2894335T5 (es) 2015-08-26 2016-08-26 Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune

Country Status (11)

Country Link
US (2) US10894831B2 (es)
EP (1) EP3341015B2 (es)
JP (3) JP7198083B2 (es)
AU (2) AU2016310348B2 (es)
CA (1) CA2996167A1 (es)
ES (1) ES2894335T5 (es)
HK (1) HK1257824A1 (es)
PL (1) PL3341015T5 (es)
PT (1) PT3341015T (es)
SI (1) SI3341015T2 (es)
WO (1) WO2017035480A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2804617T3 (da) * 2012-01-17 2020-08-10 Univ Leland Stanford Junior Højaffine sirp-alpha-reagenser
WO2016065245A1 (en) * 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
US10894831B2 (en) 2015-08-26 2021-01-19 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US10995152B2 (en) 2016-10-26 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3592387A4 (en) 2017-03-09 2021-03-31 The Board of Trustees of the Leland Stanford Junior University TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING THE CD47 SIGNAL PATH
EP4177270A1 (en) 2017-10-18 2023-05-10 Forty Seven, Inc. Anti-cd47 agent-based ovarian cancer therapy
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies unique to d47, pd-l1 and their uses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245752A1 (en) 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US8758750B2 (en) † 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
WO2011076781A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
KR20110085038A (ko) * 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
DK2804617T3 (da) 2012-01-17 2020-08-10 Univ Leland Stanford Junior Højaffine sirp-alpha-reagenser
JP6572131B2 (ja) * 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
WO2015069703A1 (en) † 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015105995A2 (en) 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
GB2532619A (en) † 2014-08-08 2016-05-25 Alexo Therapeutics Int Sirp-Alpha Variant Constructs And Uses Thereof
HUE052725T2 (hu) * 2014-08-26 2021-05-28 Univ Leland Stanford Junior Õssejtek beültetése õssejteket célzó hatóanyag és immunszabályozó szignalizáció módosításának kombinációjával
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
EP3012271A1 (en) † 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
SG10201912905VA (en) † 2015-08-07 2020-02-27 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
US10894831B2 (en) 2015-08-26 2021-01-19 The Board Of Trustees Of The Leland Stanford Junior University Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
AU2016365829B2 (en) * 2015-12-11 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of CD47 and EGFR

Also Published As

Publication number Publication date
PT3341015T (pt) 2021-10-12
HK1257824A1 (zh) 2019-11-01
US20200223923A1 (en) 2020-07-16
SI3341015T2 (sl) 2024-03-29
ES2894335T3 (es) 2022-02-14
JP2023126368A (ja) 2023-09-07
WO2017035480A1 (en) 2017-03-02
US20210095034A1 (en) 2021-04-01
US10894831B2 (en) 2021-01-19
EP3341015A4 (en) 2018-07-11
CA2996167A1 (en) 2017-03-02
SI3341015T1 (sl) 2021-11-30
AU2016310348A1 (en) 2018-03-15
JP7198083B2 (ja) 2022-12-28
EP3341015A1 (en) 2018-07-04
US11608377B2 (en) 2023-03-21
US20230257464A1 (en) 2023-08-17
EP3341015B1 (en) 2021-07-28
JP2018525421A (ja) 2018-09-06
AU2016310348B2 (en) 2023-01-05
PL3341015T5 (pl) 2024-04-08
PL3341015T3 (pl) 2021-12-13
JP2021138756A (ja) 2021-09-16
JP7313398B2 (ja) 2023-07-24
EP3341015B2 (en) 2023-12-27
AU2023201987A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
ES2894335T5 (es) Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
HK1251587A1 (zh) 抗磷脂酰肌醇蛋白多糖-3的抗體及其應用
ZA201800352B (en) Anti¿angptl8 antibodies and uses thereof
DK3374291T3 (da) Plukningssystemer og -fremgangsmåder
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
DK3113883T3 (da) Cellesorteringssystem der anvender mikrofremstillede komponenter
DK3178571T3 (da) Inspektions- og sorteringssystem
DK3379690T3 (da) Hurtigopladningsfremgangsmåde og -system
EP3709001C0 (en) SYSTEMS AND METHODS FOR DETERMINING THE OSMOLARITY OF SAMPLES
BR112016025864A2 (pt) método de lançamento do aplicativo de terminal e terminal
BR112017002600A2 (pt) aparelho de injeção e método de uso de um aparelho de injeção
GB2534557B (en) Methods and resources for creating permissions
DK3253800T3 (da) Prostata antigen standarder og bruge deraf
KR20180084858A (ko) 포커스 검출
DK3619521T3 (da) Højgennemløbssekventering med halvlederbaseret detektering
DK3184642T3 (da) Gærcelle
HK1250778A1 (zh) 分析物檢測及其方法
BR112017020146A2 (pt) método e dispositivo de configuração de portadora
DK3107935T3 (da) Komplementkomponent c5-antistoffer
DK3227079T3 (da) Fremgangsmåde til fremstilling af en isolator samt isolator
DK3108256T3 (da) Fremgangsmåde til detektering af cancer
DK3403031T3 (da) Optimeret statisk strålingskollektor
GB2534554B (en) Detecting and ranging cloud features
GB201516008D0 (en) OX40L antibodies and uses thereof
ES1146759Y (es) Hidrojardinera con drenajes